Peregrine Asset Advisers Inc. Purchases New Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Peregrine Asset Advisers Inc. purchased a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 45,703 shares of the medical equipment provider's stock, valued at approximately $3,669,000. Lantheus comprises 1.5% of Peregrine Asset Advisers Inc.'s portfolio, making the stock its 18th biggest position. Peregrine Asset Advisers Inc. owned 0.07% of Lantheus at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of LNTH. UMB Bank n.a. raised its stake in shares of Lantheus by 161.4% during the 1st quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 247 shares during the period. GAMMA Investing LLC raised its stake in shares of Lantheus by 184.1% during the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider's stock valued at $26,000 after purchasing an additional 208 shares during the period. Principal Securities Inc. bought a new stake in shares of Lantheus during the 4th quarter valued at $28,000. Fidelis Capital Partners LLC bought a new stake in shares of Lantheus during the 1st quarter valued at $34,000. Finally, FinTrust Capital Advisors LLC raised its stake in shares of Lantheus by 53.6% during the 1st quarter. FinTrust Capital Advisors LLC now owns 665 shares of the medical equipment provider's stock valued at $41,000 after purchasing an additional 232 shares during the period. 99.06% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Gary J. Pruden sold 12,530 shares of the firm's stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $95.04, for a total transaction of $1,190,851.20. Following the transaction, the director now owns 11,978 shares in the company, valued at $1,138,389.12. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Lantheus news, CAO Andrea Sabens sold 341 shares of the firm's stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $123.15, for a total value of $41,994.15. Following the completion of the sale, the chief accounting officer now owns 62,216 shares of the company's stock, valued at $7,661,900.40. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Gary J. Pruden sold 12,530 shares of the firm's stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $95.04, for a total value of $1,190,851.20. Following the completion of the sale, the director now directly owns 11,978 shares of the company's stock, valued at approximately $1,138,389.12. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 40,852 shares of company stock worth $3,922,001. Company insiders own 1.50% of the company's stock.

Analyst Upgrades and Downgrades

LNTH has been the topic of a number of analyst reports. JMP Securities decreased their price objective on Lantheus from $130.00 to $125.00 and set a "market outperform" rating on the stock in a research note on Thursday, August 1st. Redburn Atlantic began coverage on Lantheus in a research report on Tuesday, September 3rd. They set a "buy" rating and a $175.00 target price for the company. B. Riley boosted their target price on Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a research report on Thursday, July 25th. Leerink Partners boosted their target price on Lantheus from $106.00 to $127.00 and gave the stock an "outperform" rating in a research report on Thursday, July 11th. Finally, Truist Financial reduced their target price on Lantheus from $141.00 to $135.00 and set a "buy" rating for the company in a research report on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $126.00.

Lantheus Price Performance

Shares of NASDAQ LNTH traded down $1.97 during midday trading on Tuesday, reaching $105.54. 543,393 shares of the stock traded hands, compared to its average volume of 1,022,396. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.41. The stock has a market capitalization of $7.32 billion, a PE ratio of 16.41 and a beta of 0.50. Lantheus Holdings, Inc. has a one year low of $50.20 and a one year high of $126.89. The company's 50 day moving average is $105.48 and its 200 day moving average is $83.15.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The company had revenue of $394.10 million for the quarter, compared to analysts' expectations of $382.12 million. During the same quarter in the previous year, the company posted $1.40 EPS. The business's quarterly revenue was up 22.5% on a year-over-year basis. On average, equities research analysts anticipate that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.